Today, one year into the COVID-19 pandemic, we live in a changed world. With over a million deaths and many millions suffering long-term disability as a result of lasting damage done by the disease, the human and economic cost is only now taking a shape. While the arrival of various vaccines presents light at the end of the tunnel, months remain before this pandemic will be a thing of the past, and year before we will understand its fallout. As the United States and much of the rest of the world are currently bracing for a long, difficult winter, Functional Respiratory Imaging (FRI) continues to play a vital role in understanding COVID-19 and its impact on the lungs, helping healthcare providers manage the acutely ill as well as predict clinical decline, and assess who will continue to suffer after the virus has been defeated.
Fluidda started a consortium for the pharmaceutical industry to share knowledge on their COVID-19 research, knowledge that can also be of great value in the development of therapies for other lung diseases in the future. Interested in joining the Consortium? Please contact us at email@example.com
A list of current consortium members can be found here: https://www.fluidda.com/covid19/
Categorised in: Miscellaneous / January 8, 2021 3:44 pm /Tags: Consortium, COVID, COVID-19